Patient Toolkit

  • Coronavirus disease 2019 (COVID-19) is an illness caused by a virus that can spread from person to person, including by people who appear to have no symptoms.

  • Coronavirus can spread through respiratory droplets when an infected person coughs, sneezes, or talks. You may also get the virus by touching objects contaminated with the virus and then touching your mouth, eyes, or nose.

  • Wash your hands often with soap and water for at least 20 seconds, or use an alcohol-based hand sanitizer that contains at least 60% alcohol to prevent the spread of the virus.


COVID-19 is an infectious disease caused by a newly discovered coronavirus. Although most people infected with the COVID-19 virus will experience mild symptoms, up to 20% of people will be hospitalized with this virus and some may die. The best way to prevent and slow down transmission is to be well informed about the COVID-19 virus. In this Patient Toolkit, you will find information on the symptoms of COVID-19 and risk factors for severe disease, as well as answers to frequently asked questions.

Click on the links below to begin exploring the COVID FRONTLINE initiative.

Copyright © 2020 | COVID Frontline | All Rights Reserved | Website by Divigner

Patient Toolkit

The COVID FRONTLINE Patient Toolkit is a resource center for patients who have been diagnosed with or who are interested in learning about COVID-19. Choose from the options below to learn more.

Clinical Toolkit

The COVID-19 Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for COVID-19. Click on one of the options below to learn more.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Merck & Co., Inc., and Pfizer.

Copyright © 2019 | COVID Frontline | All Rights Reserved | Website by Divigner

Updates in the Treatment and Prevention of COVID-19​

Vaccine candidate BNT162b2 found to be 95% effective

Primary efficacy analysis of the vaccine candidate BNT162b2 found it to be 95% effective against COVID-19 beginning 28 days after the first dose. The efficacy was consistent across all age, gender, race, and ethnicity demographics. The observed efficacy in adults over 65 years of age was 94%. The phase 3 trial enrolled more than 43,000 subjects, with 162 confirmed COVID-19 cases observed in the placebo group versus 8 in the vaccine group. Pfizer and BioNtech report that the vaccine was well tolerated across all populations with no serious safety concerns observed. The only grade 3 adverse events with a frequency ≥2% were fatigue (3.8%) and headache (2.0%).1

Emergency use authorization granted for baricitinib plus remdesivir

The US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for baricitinib in combination with remdesivir for hospitalized adults and children at least 2 years old with suspected or confirmed COVID-19 who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).2 Baricitinib plus remdesivir was shown to significantly reduce the time to recovery within 29 days of initiating therapy compared with placebo plus remdesivir (7 vs 8 days, respectively; P= .04). The odds of improvement in clinical status at day 15 were 30% greater in patients treated with baricitinib plus remdesivir compared with remdesivir alone (odds ratio, 1.3; P= .04).3

Treating recently diagnosed COVID-19

The FDA granted an EUA to the investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg for the treatment of mild-to-moderate COVID-19 in patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. The EUA is based on data from the randomized, placebo-controlled, phase 2 BLAZE-1 study. Patients treated with bamlanivimab in the outpatient setting showed reduced viral load and lower rates of symptoms and hospitalization.4

Interim analysis of vaccine candidate mRNA-1273 demonstrates 94.5% efficacy

An interim analysis of a phase 3 trial of the vaccine candidate mRNA-1273 demonstrated a vaccine efficacy of 94.5% against COVID-19. The trial enrolled more than 30,000 participants, with 90 cases of COVID-19 observed in the placebo group versus 5 cases in the vaccine group. Moderna reported that the vaccine was well tolerated. Grade 3 adverse events with a frequency ≥2% included injection-site pain (2.7%) after the first injection and fatigue (9.7%), myalgia (8.9%), arthralgia (5.2%), headache (4.5%), pain (4.1%), and redness at the injection site (2.0%) after the second injection.5


  1. Pfizer press release. Pfizer and BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints. November 18, 2020. Available at
  2. Lilly press release. Baricitinib receives emergency use authorization from the FDA for the treatment of hospitalized patients with COVID-19. November 19, 2020. Available at
  3. Lilly press release. Baricitinib has significant effect on recovery time, most impactful in COVID-19 patients requiring oxygen. October 8, 2020. Available at
  4. Lilly press release. Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19. November 9, 2020. Available at
  5. Moderna press release. Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study. November 16, 2020. Available at